Epix Pharmaceuticals, Inc.
Records under this name other than patents Epix Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Epix Pharmaceuticals, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,034,898 | Methods of Collagen Imaging now held by Collagen Medical, LLC In force · High confidence | In force | High confidence | |
| US 7,927,581 | Peptide-Based Multimeric Targeted Contrast Agents now held by Factor 1A, LLC Term ended Term ended May 28, 2025 · High confidence | Term ended | Term ended May 28, 2025 | High confidence |
| US 7,238,341 | Peptide-Based Multimeric Targeted Contrast Agents now held by Factor 1A, LLC Term ended Term ended Sep 11, 2022 · High confidence | Term ended | Term ended Sep 11, 2022 | High confidence |
| US 6,991,775 | Peptide-Based Multimeric Targeted Contrast Agents now held by Factor 1A, LLC Term ended Term ended Jul 30, 2022 · High confidence | Term ended | Term ended Jul 30, 2022 | High confidence |
| US 6,676,929 | Diagnostic Imaging Contrast Agents with Extended Blood Retention now held by Lantheus Medical Imaging, Inc. Term ended Term ended May 4, 2020 · Medium confidence | Term ended | Term ended May 4, 2020 | Medium confidence |
| US 7,855,193 | S1P Receptor Modulating Compounds and Use Thereof now held by Amgen Inc. Lapsed on the fee record Ended Dec 21, 2018 · High confidence | Lapsed on the fee record | Ended Dec 21, 2018 | High confidence |
| US 7,790,707 | S1P Receptor Modulating Compounds and Use Thereof now held by Amgen Inc. Lapsed on the fee record Ended Sep 7, 2018 · High confidence | Lapsed on the fee record | Ended Sep 7, 2018 | High confidence |
| US 6,969,507 | Imaging Sexual Response now held by Lantheus Medical Imaging, Inc. Lapsed on the fee record Ended Nov 29, 2017 · Medium confidence | Lapsed on the fee record | Ended Nov 29, 2017 | Medium confidence |
| US 7,175,829 | Contrast-Enhanced Diagnostic Imaging Method for Monitoring Interventional Therapies now held by Lantheus Medical Imaging, Inc. Term ended Ended no later than Oct 2, 2017 · Low confidence | Term ended | Ended no later than Oct 2, 2017 | Low confidence |
| US 8,080,542 | S1P Receptor Modulating Compounds and Use Thereof now held by Amgen Inc. Lapsed on the fee record Ended Dec 20, 2015 · High confidence | Lapsed on the fee record | Ended Dec 20, 2015 | High confidence |